Reading the 4Ts Score for Heparin-Induced Thrombocytopenia: What Each Point Measures

The 4Ts score rates four features of suspected heparin-induced thrombocytopenia (HIT), assigning 0, 1, or 2 points to each for a maximum of 8. A low total of 3 or under makes HIT very unlikely, and the 2018 American Society of Hematology (ASH) guideline treats that result as a reason to stop the workup rather than order antibody tests. Intermediate and high scores push the other way: stop heparin, start a non-heparin anticoagulant, and send confirmatory testing. The score does not diagnose HIT. It sorts patients into those who need a laboratory answer and those who almost certainly do not.

Why a clinical score comes before the lab

HIT is an immune reaction in which antibodies against platelet factor 4 (PF4) bound to heparin activate platelets, dropping the platelet count while paradoxically driving clotting. The danger is real, but the clinical picture is common and non-specific: hospitalized patients drop their platelets for dozens of reasons. If every dip triggered a full immunologic workup and a switch to an alternative anticoagulant, most of that testing and treatment would land on people who never had HIT.

The 4Ts score, developed by Warkentin and colleagues, exists to bring order to that problem. It formalizes the bedside judgment a hematologist would apply anyway, turning it into a reproducible number that can be scored before any assay returns. The ASH 2018 guideline, published in Blood Advances, builds its diagnostic pathway on this pretest probability rather than on lab testing alone, because the value of a PF4 antibody test depends heavily on how likely HIT was in the first place.

What each of the four Ts measures

Each category earns 0, 1, or 2 points. The higher the points, the more the feature resembles classic HIT.

Thrombocytopenia

This scores the depth of the platelet fall and how low it lands. A drop of more than 50 percent from baseline with a nadir of at least 20 x 10⁹/L earns the full 2 points, because that pattern fits immune-mediated destruction. A smaller fall, or a nadir so low it suggests something else is consuming platelets, earns fewer points. The category rewards a substantial but not catastrophic decline, which is the HIT signature.

Timing

This is the most distinctive feature. Classic HIT antibodies appear 5 to 10 days after heparin starts, so a platelet fall in that window scores 2 points. A rapid fall within a day also scores 2 if the patient had heparin exposure in the prior 30 days, because pre-formed antibodies can act immediately. A fall that is too early with no prior exposure, or that cannot be timed, scores lower. Timing carries so much weight because few competing causes follow this precise schedule.

Thrombosis

New confirmed thrombosis, skin necrosis at heparin injection sites, or a systemic reaction after an intravenous heparin bolus earns 2 points. Progressive or recurrent thrombosis, or suspected but unproven clot, earns 1. This category reflects that HIT is a prothrombotic disorder, so a fresh clot alongside falling platelets raises suspicion.

oTher causes

The final T is subtractive in spirit. It asks whether another explanation for the thrombocytopenia is present. If no alternative is apparent, the patient earns 2 points. If a possible competing cause exists, such as sepsis or another drug, points fall. This is the category that keeps the score honest, forcing the scorer to weigh the many non-HIT reasons platelets drop in sick patients.

What a low, intermediate, or high total is meant to trigger

Totals map to three tiers. A score of 3 or under is low probability, 4 to 5 is intermediate, and 6 to 8 is high.

The strength of the low tier is well documented. A 2012 systematic review and meta-analysis by Cuker and colleagues in Blood pooled 13 studies and more than 3,000 patients and found the negative predictive value of a low 4Ts score was roughly 0.998. More than half the patients in those studies scored low. In practical terms, a low score is a robust way to rule HIT out, which is why the ASH guideline advises against both antibody testing and empiric non-heparin anticoagulation when the score is low. The same meta-analysis showed the score is far weaker at ruling HIT in: the positive predictive value of an intermediate score was only about 0.14 and of a high score about 0.64. A high score raises concern but does not confirm the diagnosis.

That asymmetry shapes the guideline pathway. For an intermediate or high score, ASH recommends stopping heparin and starting a non-heparin anticoagulant while testing proceeds, because the cost of waiting on a true HIT case is dangerous clotting. Anticoagulation intensity is individualized to bleeding risk. Testing then moves in two steps: a PF4 antibody immunoassay first, and if it is positive and a functional assay such as the serotonin release assay (SRA) is available, confirmatory functional testing. The immunoassay is sensitive but not specific, so a functional assay, which measures whether the antibodies actually activate platelets, sharpens the diagnosis before a patient is committed to a HIT label and its downstream consequences.

The limits worth keeping in view

The score depends on who is scoring it. Agreement between raters is imperfect, and the timing and other-causes categories in particular call for judgment about baseline platelet counts and competing diagnoses that may not be obvious at the bedside. The reassuring negative predictive value of a low score is strongest in the study populations examined, where HIT prevalence was modest; the tool performs best as a rule-out and worst as a stand-alone rule-in. It is a triage instrument, not a verdict.

This article is educational and is not medical advice; decisions about anticoagulation belong to a patient and their treating clinician. The point of the 4Ts score is narrower than it looks. It does not tell anyone they have HIT. It tells the team whether a laboratory answer is worth chasing, and when a low number should end the conversation instead of starting a cascade of tests and drug switches.